Description

Eli Lilly Has Dominated Weight Loss—Now It Is Coming for Cancer!

Eli Lilly has become one of the most recognizable names in global healthcare because of Mounjaro and Zepbound, the blockbuster medicines that helped reshape the obesity and diabetes markets. Yet an increasingly important part of the company’s growth story is developing outside GLP-1 drugs. Lilly is expanding its oncology portfolio across pancreatic cancer, breast cancer, lung cancer, chronic lymphocytic leukemia, multiple myeloma and other difficult-to-treat diseases. The latest development came when the FDA granted orphan drug designation to olomorasib, Lilly’s experimental therapy targeting KRAS G12C-mutated cancers, following an earlier Breakthrough Therapy designation in a specific pancreatic cancer setting. Although neither designation represents commercial approval, the regulatory progress comes alongside encouraging clinical data from several other Lilly cancer programs, growing sales from existing oncology products and acquisitions designed to add new technologies.